Giant Biogene Holding (SEHK:2367): Assessing Valuation After Launching a 10% Share Buyback Program

Simply Wall St.2025-12-23

Giant Biogene Holding (SEHK:2367) has kicked off a sizeable share repurchase program, with approval to buy back up to 10% of its share capital. This move puts capital allocation firmly in the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593466790?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278","is_english":true,"pubTime":"2025-12-23 08:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593466790","market":"sg","top_or_hot":-1,"title":"Giant Biogene Holding (SEHK:2367): Assessing Valuation After Launching a 10% Share Buyback Program","media":"Simply Wall St.","content":"<div>\n<p>Giant Biogene Holding (SEHK:2367) has kicked off a sizeable share repurchase program, with approval to buy back up to 10% of its share capital. This move puts capital allocation firmly in the ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk2367-assessing-valuation-after-lau\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Giant Biogene Holding (SEHK:2367): Assessing Valuation After Launching a 10% Share Buyback Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGiant Biogene Holding (SEHK:2367): Assessing Valuation After Launching a 10% Share Buyback Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 08:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk2367-assessing-valuation-after-lau><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Giant Biogene Holding (SEHK:2367) has kicked off a sizeable share repurchase program, with approval to buy back up to 10% of its share capital. This move puts capital allocation firmly in the ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk2367-assessing-valuation-after-lau\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk2367-assessing-valuation-after-lau","article_id":"2593466790","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk2367-assessing-valuation-after-lau","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593466790","pubTimestamp":1766450404,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Giant Biogene Holding (SEHK:2367) has kicked off a sizeable share repurchase program, with approval to buy back up to 10% of its share capital. This move puts capital allocation firmly in the spotlight for investors.\nSee our latest analysis for Giant Biogene Holding.\nThe buyback comes after a tough stretch, with a 90 day share price return of negative 41.32 percent, but a recent 4.40 percent 7 day share price return around HK$36.06 hints that sentiment may be stabilising rather than sliding...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","BK1207":"个人用品","02367":"巨子生物","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"Biant Biogene Holding(SEHK：2367)：启动10%股票回购计划后评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"02367":0.9},"content_text":"Giant Biogene Holding (SEHK:2367) has kicked off a sizeable share repurchase program, with approval to buy back up to 10% of its share capital. This move puts capital allocation firmly in the spotlight for investors. See our latest analysis for Giant Biogene Holding. The buyback comes after a tough stretch, with a 90 day share price return of negative 41.32 percent, but a recent 4.40 percent 7 day share price return around HK$36.06 hints that sentiment may be stabilising rather than sliding further. If this buyback has you rethinking where growth and conviction might overlap, it could be worth exploring fast growing stocks with high insider ownership as a way to spot other potential standouts. With earnings and revenue still growing and the share price well below analyst targets, is Giant Biogene quietly trading at a discount, or is the market already bracing for a slowdown in its future growth? Price-to-Earnings of 15.4x: Is it justified? On a price-to-earnings ratio of 15.4x and a last close of HK$36.06, Giant Biogene screens as undervalued versus both its peers and its own fundamentals. The price-to-earnings multiple compares the company’s current share price with its earnings per share, making it a core yardstick for profitable, growing consumer and personal products businesses like Giant Biogene. Here, the market is paying substantially less per unit of earnings than it does for comparable personal products stocks, even though Giant Biogene combines high quality earnings, robust historical profit growth of roughly the high twenties per year, and a strong return on equity already in the mid twenties, with forecasts pointing higher. Relative to the wider Asian Personal Products industry average P/E of 23.8x and a peer average of 21.8x, Giant Biogene’s 15.4x looks like a steep discount that could narrow if its above market earnings and revenue growth, as well as its high forecast return on equity, continue to materialise alongside the estimated fair price to earnings level of 23.1x. Explore the SWS fair ratio for Giant Biogene Holding Result: Price-to-Earnings of 15.4x (UNDERVALUED) However, investors should still watch for slower consumer spending or intensifying competition in China, which could cap growth and prevent that valuation gap from closing. Find out about the key risks to this Giant Biogene Holding narrative. Another View on Value Our DCF model paints a similar picture, suggesting Giant Biogene is trading around 43.7 percent below its fair value estimate of HK$64.08. If both earnings multiples and cash flow point to upside, is this a classic value opportunity or a sign the market sees risks others are missing? Look into how the SWS DCF model arrives at its fair value. 2367 Discounted Cash Flow as at Dec 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Giant Biogene Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 899 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Giant Biogene Holding Narrative If you see the story differently or want to dig into the numbers yourself, you can build a personalised view in just minutes, starting with Do it your way. A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Giant Biogene Holding. Ready for more high conviction ideas? Do not stop with a single stock when you can systematically uncover more opportunities. Let the Simply Wall St Screener work hard while you stay ahead.  Capture potential mispricings by scanning these 899 undervalued stocks based on cash flows that could reward patience when the market finally catches up. Position yourself for the next wave of innovation by targeting these 24 AI penny stocks that may reshape entire industries. Lock in reliable income streams by focusing on these 10 dividend stocks with yields > 3% that can help support long term returns through different market cycles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentNew: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593466790","isCrawlerRequest":true}